The timing of perioperative interruption of anticoagulation is dependant on pharmacokinetic considerations instead of on evidence from clinical trials. the clotting elements IIa (dabigatran) and Xa (rivaroxaban, apixaban). The timing of perioperative interruption of anticoagulation is dependant on pharmacokinetic considerations instead of on proof from clinical studies. Recent studies show that substituting short-acting anticoagulants for … Continue reading The timing of perioperative interruption of anticoagulation is dependant on pharmacokinetic considerations instead of on evidence from clinical trials